Cholesterol levels in HIV-HCV infected patients treated with lopinavir/r: results from the SCOLTA project.

Abstract

BACKGROUND:

It is not known whether antiretroviral therapy (ART) including lopinavir/r has a different effect on the lipid metabolism in HIV patients co-infected with HCV. This study investigated changes in lipid levels, comparing patients with HIV infection alone and those with HCV too, in the lopinavir/r cohort of the SCOLTA project.

METHODS:

We analyzed the data for the lopinavir/r nationwide cohort from 25 Italian infectious disease departments, which comprises 743 HIV-infected patients followed prospectively, comparing subjects with HIV-HCV co-infection and those with single-infection.

RESULTS:

At enrolment, co-infected patients had significantly lower mean cholesterol than HCV negative cases (162+/-43mg/dL vs. 185+/-52mg/dL, p=0.0009). Total and non-HDL cholesterol and triglycerides rose significantly from baseline in HIV single-infection patients, but not in those with co-infection. The patients with dual HIV-HCV infection, treated with an ART regimen including lopinavir/r, have only limited increases in total and non-HDL cholesterol and triglycerides.

CONCLUSIONS:

Changes in serum lipids in co-infected patients differed significantly from those in patients without HCV. It remains to be seen whether this is associated with a lower risk of progression of atherosclerotic disease.

• Authors: Giuseppe Vittorio L De Socio, Paolo Bonfanti, Elena Ricci, Giancarlo Orofino, Giordano Madeddu, Giovanni Penco, Erika Gianelli, Canio Martinelli, Silvia Carradori, Tiziana Quirino, Giuliano Rizzardini, CISAI Study Group
• Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (Biomed Pharmacother) Vol. 62 Issue 1 Pg. 16-20 (Jan 2008) ISSN: 0753-3322 [Print] France
• PMID: 17851026 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-HIV Agents
• Drug Combinations
• HIV Protease Inhibitors
• Pyrimidinones
• Triglycerides
• Lopinavir
• Cholesterol
• Ritonavir

Topics

• Adult
• Anti-HIV Agents (adverse effects, therapeutic use)
• Cholesterol (blood)
• Cohort Studies
• Drug Combinations
• Female
• Follow-Up Studies
• HIV Infections (complications, drug therapy)
• HIV Protease Inhibitors (adverse effects, therapeutic use)
• Hepatitis C, Chronic (complications)
• Humans
• Lopinavir
• Male
• Middle Aged
• Prospective Studies
• Pyrimidinones (adverse effects, therapeutic use)
• Ritonavir (adverse effects, therapeutic use)
• Triglycerides (blood)